Table 5.

Associations between baseline lipoprotein measures and the rate of eGFR decline stratified by proteinuria at baseline in the Chronic Renal Insufficiency Cohort study

Lipoprotein24-hr Urinary Protein≤0.2 g/d24-hr Urinary Protein>0.2 g/d
Slope Differenceb per 1 SD Higher of Lipoprotein Variable (95% CI) P ValueSlope Differenceb per 1 SD Higher of Lipoprotein Variable (95% CI)P Value
Total cholesterol0.10 (−0.05 to 0.25)0.19−0.12 (−0.29 to 0.06)0.19
LDL cholesterol0.11 (−0.04 to 0.25)0.15−0.03 (−0.20 to 0.13)0.68
HDL cholesterol−0.01 (−0.14 to 0.12)0.86−0.05 (−0.24 to 0.14)0.59
VLDL cholesterolb0.06 (−0.06 to 0.19)0.34−0.06 (−0.23 to 0.10)0.46
Triglyceridesb0.09 (−0.04 to 0.22)0.19−0.02 (−0.18 to 0.15)0.84
Lp(a)b0.04 (−0.09 to 0.17)0.52−0.03 (−0.21 to 0.15)0.73
ApoA-I0.07 (−0.06 to 0.21)0.29−0.04 (−0.23 to 0.15)0.70
ApoB0.15 (0.01 to 0.29)0.03−0.04 (−0.22 to 0.13)0.61
  • Lp(a), lipoprotein(a).

  • a Model adjusted for age, race, sex, diabetes, BP, statin use at baseline, smoking, 24-hour urine protein excretion, body mass index, clinical center, alcohol use, and baseline eGFR per 1-SD change in independent variable. Slope difference in ml/min per 1.73 m2 per year; a negative slope difference indicates a faster decline in GFR.

  • b Values were log transformed.